237 related articles for article (PubMed ID: 15252137)
1. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.
Ihle NT; Williams R; Chow S; Chew W; Berggren MI; Paine-Murrieta G; Minion DJ; Halter RJ; Wipf P; Abraham R; Kirkpatrick L; Powis G
Mol Cancer Ther; 2004 Jul; 3(7):763-72. PubMed ID: 15252137
[TBL] [Abstract][Full Text] [Related]
2. In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316.
Meuillet EJ; Ihle N; Baker AF; Gard JM; Stamper C; Williams R; Coon A; Mahadevan D; George BL; Kirkpatrick L; Powis G
Oncol Res; 2004; 14(10):513-27. PubMed ID: 15559765
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.
Sajithlal GB; Hamed HA; Cruickshanks N; Booth L; Tavallai S; Syed J; Grant S; Poklepovic A; Dent P
Mol Pharmacol; 2013 Oct; 84(4):562-71. PubMed ID: 23877009
[TBL] [Abstract][Full Text] [Related]
4. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
Ihle NT; Paine-Murrieta G; Berggren MI; Baker A; Tate WR; Wipf P; Abraham RT; Kirkpatrick DL; Powis G
Mol Cancer Ther; 2005 Sep; 4(9):1349-57. PubMed ID: 16170026
[TBL] [Abstract][Full Text] [Related]
5. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures.
Howes AL; Chiang GG; Lang ES; Ho CB; Powis G; Vuori K; Abraham RT
Mol Cancer Ther; 2007 Sep; 6(9):2505-14. PubMed ID: 17766839
[TBL] [Abstract][Full Text] [Related]
6. The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling.
Williams R; Baker AF; Ihle NT; Winkler AR; Kirkpatrick L; Powis G
Cancer Chemother Pharmacol; 2006 Oct; 58(4):444-50. PubMed ID: 16485116
[TBL] [Abstract][Full Text] [Related]
7. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice.
Ng SS; Tsao MS; Nicklee T; Hedley DW
Clin Cancer Res; 2001 Oct; 7(10):3269-75. PubMed ID: 11595724
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.
Ihle NT; Lemos R; Schwartz D; Oh J; Halter RJ; Wipf P; Kirkpatrick L; Powis G
Mol Cancer Ther; 2009 Jan; 8(1):94-100. PubMed ID: 19139117
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin.
Hayakawa J; Ohmichi M; Kurachi H; Kanda Y; Hisamoto K; Nishio Y; Adachi K; Tasaka K; Kanzaki T; Murata Y
Cancer Res; 2000 Nov; 60(21):5988-94. PubMed ID: 11085518
[TBL] [Abstract][Full Text] [Related]
10. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.
Rudolph D; Steegmaier M; Hoffmann M; Grauert M; Baum A; Quant J; Haslinger C; Garin-Chesa P; Adolf GR
Clin Cancer Res; 2009 May; 15(9):3094-102. PubMed ID: 19383823
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.
Ihle NT; Lemos R; Wipf P; Yacoub A; Mitchell C; Siwak D; Mills GB; Dent P; Kirkpatrick DL; Powis G
Cancer Res; 2009 Jan; 69(1):143-50. PubMed ID: 19117997
[TBL] [Abstract][Full Text] [Related]
12. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
Yuan J; Mehta PP; Yin MJ; Sun S; Zou A; Chen J; Rafidi K; Feng Z; Nickel J; Engebretsen J; Hallin J; Blasina A; Zhang E; Nguyen L; Sun M; Vogt PK; McHarg A; Cheng H; Christensen JG; Kan JL; Bagrodia S
Mol Cancer Ther; 2011 Nov; 10(11):2189-99. PubMed ID: 21750219
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin.
Wipf P; Minion DJ; Halter RJ; Berggren MI; Ho CB; Chiang GG; Kirkpatrick L; Abraham R; Powis G
Org Biomol Chem; 2004 Jul; 2(13):1911-20. PubMed ID: 15227545
[TBL] [Abstract][Full Text] [Related]
14. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.
Hikichi Y; Honda K; Hikami K; Miyashita H; Kaieda I; Murai S; Uchiyama N; Hasegawa M; Kawamoto T; Sato T; Ichikawa T; Cao S; Nie Z; Zhang L; Yang J; Kuida K; Kupperman E
Mol Cancer Ther; 2012 Mar; 11(3):700-9. PubMed ID: 22188812
[TBL] [Abstract][Full Text] [Related]
15. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival.
Carón RW; Yacoub A; Li M; Zhu X; Mitchell C; Hong Y; Hawkins W; Sasazuki T; Shirasawa S; Kozikowski AP; Dennis PA; Hagan MP; Grant S; Dent P
Mol Cancer Ther; 2005 Feb; 4(2):257-70. PubMed ID: 15713897
[TBL] [Abstract][Full Text] [Related]
16. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
17. Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase.
Lemke LE; Paine-Murrieta GD; Taylor CW; Powis G
Cancer Chemother Pharmacol; 1999; 44(6):491-7. PubMed ID: 10550570
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.
Yaguchi S; Fukui Y; Koshimizu I; Yoshimi H; Matsuno T; Gouda H; Hirono S; Yamazaki K; Yamori T
J Natl Cancer Inst; 2006 Apr; 98(8):545-56. PubMed ID: 16622124
[TBL] [Abstract][Full Text] [Related]
19. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells.
Wang HQ; Altomare DA; Skele KL; Poulikakos PI; Kuhajda FP; Di Cristofano A; Testa JR
Oncogene; 2005 May; 24(22):3574-82. PubMed ID: 15806173
[TBL] [Abstract][Full Text] [Related]
20. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.
Rhodes N; Heerding DA; Duckett DR; Eberwein DJ; Knick VB; Lansing TJ; McConnell RT; Gilmer TM; Zhang SY; Robell K; Kahana JA; Geske RS; Kleymenova EV; Choudhry AE; Lai Z; Leber JD; Minthorn EA; Strum SL; Wood ER; Huang PS; Copeland RA; Kumar R
Cancer Res; 2008 Apr; 68(7):2366-74. PubMed ID: 18381444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
